EUVIMEDEUVIMED entdecken
Open Access

CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy

Yongji Zhang, Honghong Zou, Xinran Ni iD, Fenghong Tie, Boyang Xu, Yuqi Kang, Weiyi Xiang, Yaxin Li iD, Changhao Jia iD, Ying Tan iD, Lijun Liu iD, Jicheng Lv und 6 weitere

Journal of the American Society of Nephrology · 2026

DOI: 10.1681/asn.0000000983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2026. Verfasst von Yongji Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Complement Activation, Complement C3b Inactivator Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Beijing New-star Plan of Science and Technology, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points CFHR3*B haplotype was a susceptibility variant for IgA nephropathy diagnosis by enhancing complement activation. The rs446868A variant in CFHR3*B elevated CFHR3 transcription and was associated with higher circulating FHR3 levels in patients with IgA nephropathy. FHR3241Ser variant enhanced C3b binding and complement activation, accelerating IgA deposition–induced complement activation in IgA nephropathy.

Background

Complement activation is involved in IgA nephropathy. We previously identified that genetic deletion of CFHR3 and CFHR1 confers protection against IgA nephropathy by modulating complement activation. In addition, the CFHR3*B haplotype (rs385390C/rs446868A/rs138675433T/rs149352569T) has been linked to elevated CFHR3 transcription and higher risk of atypical hemolytic uremic syndrome.

Methods

We evaluated the association between the CFHR3*B haplotype and IgA nephropathy susceptibility by using genetic analysis of 1108 patients with IgA nephropathy and 630 healthy controls. Luciferase activity assays were performed to assess the transcriptional activity of CFHR3*B haplotype. The coding variant rs138675433 (FHR3 241Pro versus FHR3 241Ser ) was assessed using recombinant proteins to determine its effect on complement regulation.

Results

The CFHR3*B haplotype and CFHR3*BB genotype were significantly enriched in patients with IgA nephropathy. The CFHR3*BB genotype correlated with lower circulating C3 levels and greater glomerular C3 deposition. Luciferase activity assays demonstrated enhanced transcription activity conferred by the CFHR3*B haplotype, with rs446868 identified as the functional regulatory variant. Patients carrying the CFHR3*BB genotype exhibited elevated circulating FHR3 levels. FHR3 241Ser exhibited significantly enhanced C3b-binding capacity and factor H deregulation activity, promoting accelerated C3 convertase formation and increased hemolysis. Furthermore, FHR3 241Ser augmented IgA deposition–induced complement activation on cultured mesangial cells in a dose-dependent manner.

Conclusions

Our results identified CFHR3*B haplotype as a susceptibility variant for IgA nephropathy diagnosis by accelerating complement activation, through rs446868A enhancing transcription activity and rs138675433T augmenting FHR3 function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAComplement ActivationComplement C3b Inactivator ProteinsHumansHaplotypesMaleFemaleGenetic Predisposition to DiseaseAdultPolymorphism, Single NucleotideMiddle AgedBlood Proteins

Stichwörter der Autor:innen

IGA nephropathycomplement

Substanzen

CFHR3 protein, humanComplement C3b Inactivator ProteinsBlood Proteins

Autor:innen und Institutionen

  • Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
  • Peking University Institute of Nephrology, Beijing, China.
  • Key Laboratory of Renal Disease (Peking University), National Health Commission, Beijing, China.
  • Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing, China.
  • State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
  • Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

ORCID-Profile: Xinran Ni, Yaxin Li, Changhao Jia, Ying Tan, Lijun Liu, Junyu Xiao, Li Zhu, Hong Zhang

Förderung

  • National Natural Science Foundation of China
  • Beijing New-star Plan of Science and Technology
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, Y., Zou, H., Ni, X., Tie, F., Xu, B., Kang, Y., Xiang, W., Li, Y., Jia, C., Tan, Y., Liu, L., Lv, J., Xiao, J., Xu, G., Yu, L., Zhao, M., Zhu, L., & Zhang, H. (2026). CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000000983

Vancouver

Zhang Y, Zou H, Ni X, Tie F, Xu B, Kang Y, et al. CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000000983

BibTeX
@article{Zhang2026,
  author = {Zhang, Yongji and Zou, Honghong and Ni, Xinran and Tie, Fenghong and Xu, Boyang and Kang, Yuqi and Xiang, Weiyi and Li, Yaxin and Jia, Changhao and Tan, Ying and Liu, Lijun and Lv, Jicheng and Xiao, Junyu and Xu, Gaosi and Yu, Lei and Zhao, Minghui and Zhu, Li and Zhang, Hong},
  title = {CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000000983}
}
Kostenlos starten →